Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry.bsky.social
Physician-Scientist Oncologist, Director Legorreta Cancer Center, Associate Dean, past Faculty Exec Cmte member, Brown Univ, ACS Professor, Chair, WIN Consortium in Precision Oncology, Entrepreneur, Boat Captain, joined Nov 16 ‘24 Pubs: tinyurl.com/s98xg3u
Looking forward to attending and presenting a keynote lecture at the 18th BGIICC 2026 Breast Gynecological & Immuno-oncology International Cancer Conference in Cairo, Egypt.
January 19, 2026 at 5:56 PM
Looking forward to attending and presenting a keynote lecture at the 18th BGIICC 2026 Breast Gynecological & Immuno-oncology International Cancer Conference in Cairo, Egypt.
Snowy morning in Providence at start of business travel.
January 18, 2026 at 1:05 PM
Snowy morning in Providence at start of business travel.
Happy Friday from the Ocean State’s Legorreta Cancer Center at Brown University.
There is much progress and momentum in the fight against cancer in Rhode Island.
2026 is shaping up as a great year at Brown’s superb academic environment. @BrownUCancer @BrownMedicine @BrownUniversity
There is much progress and momentum in the fight against cancer in Rhode Island.
2026 is shaping up as a great year at Brown’s superb academic environment. @BrownUCancer @BrownMedicine @BrownUniversity
January 16, 2026 at 2:04 PM
Happy Friday from the Ocean State’s Legorreta Cancer Center at Brown University.
There is much progress and momentum in the fight against cancer in Rhode Island.
2026 is shaping up as a great year at Brown’s superb academic environment. @BrownUCancer @BrownMedicine @BrownUniversity
There is much progress and momentum in the fight against cancer in Rhode Island.
2026 is shaping up as a great year at Brown’s superb academic environment. @BrownUCancer @BrownMedicine @BrownUniversity
Lots of progress at Danoff Life Sciences Research Building in Providence’s Jewelry District @BrownMedicine
#LegorretaCancerCenter @BrownUCancer @BrownUnivHealth
#LegorretaCancerCenter @BrownUCancer @BrownUnivHealth
January 14, 2026 at 1:48 PM
Lots of progress at Danoff Life Sciences Research Building in Providence’s Jewelry District @BrownMedicine
#LegorretaCancerCenter @BrownUCancer @BrownUnivHealth
#LegorretaCancerCenter @BrownUCancer @BrownUnivHealth
Capturing the Lighthouse in Barrington, Rhode Island during a spectacular sunset.
January 12, 2026 at 9:38 PM
Capturing the Lighthouse in Barrington, Rhode Island during a spectacular sunset.
Back to clinic today where we are wearing masks throughout the hospital. Opportunity to mention benefits of physical activity for early stage treated colorectal cancer to reduce fatigue and improve QoL based on what was learned at #GI26 @ASCO on Saturday in San Francisco.
January 12, 2026 at 9:18 PM
Back to clinic today where we are wearing masks throughout the hospital. Opportunity to mention benefits of physical activity for early stage treated colorectal cancer to reduce fatigue and improve QoL based on what was learned at #GI26 @ASCO on Saturday in San Francisco.
Censored on LinkedIn.
January 11, 2026 at 5:02 AM
Censored on LinkedIn.
Thank you Sydney Towle for sharing your experiences and insights with the @ASCO GI #GI26 community.
Your powerful words are heard and understood.
Your powerful words are heard and understood.
January 10, 2026 at 6:34 PM
Thank you Sydney Towle for sharing your experiences and insights with the @ASCO GI #GI26 community.
Your powerful words are heard and understood.
Your powerful words are heard and understood.
Great to meet with colleagues Stephen Ford and @Brooke_PhD at @Amgen @AmgenOncology to discuss collaboration on specific therapeutic areas and precision oncology opportunities with @WIN_Consortium @BrownUCancer
January 10, 2026 at 1:35 AM
Great to meet with colleagues Stephen Ford and @Brooke_PhD at @Amgen @AmgenOncology to discuss collaboration on specific therapeutic areas and precision oncology opportunities with @WIN_Consortium @BrownUCancer
Enjoyable meal of kofta, falafel, tahini, lentil soup, and Mountain Dew at Oasis Grill across the street from Moscone Center where #GI26 is taking place.
January 9, 2026 at 11:06 PM
Enjoyable meal of kofta, falafel, tahini, lentil soup, and Mountain Dew at Oasis Grill across the street from Moscone Center where #GI26 is taking place.
Important talk at #GI26 highlighting guidance to test patients planned to receive a fluoropyrimidine for DPYD variant testing. Uridine triacetate rapid reversal agent.
Capecitabine's Black Box Warning:
Practical Considerations for DPD
Deficiency in Treatment Decisions by Thomas Holden, MD, Stanford
Capecitabine's Black Box Warning:
Practical Considerations for DPD
Deficiency in Treatment Decisions by Thomas Holden, MD, Stanford
January 9, 2026 at 10:53 PM
Important talk at #GI26 highlighting guidance to test patients planned to receive a fluoropyrimidine for DPYD variant testing. Uridine triacetate rapid reversal agent.
Capecitabine's Black Box Warning:
Practical Considerations for DPD
Deficiency in Treatment Decisions by Thomas Holden, MD, Stanford
Capecitabine's Black Box Warning:
Practical Considerations for DPD
Deficiency in Treatment Decisions by Thomas Holden, MD, Stanford
Excellent presentation on Resistance to Treatments Targeting the RAS/RAF/MEK Pathways by Sandra Misale, PhD,
Johns Hopkins at #GI26
Genetic, nongenetic mechanisms, reshaping TME. Different patterns of resistance seen between inhibitors of specific KRAS alleles vs pan-RAS inhibitors.
Johns Hopkins at #GI26
Genetic, nongenetic mechanisms, reshaping TME. Different patterns of resistance seen between inhibitors of specific KRAS alleles vs pan-RAS inhibitors.
January 9, 2026 at 10:43 PM
Excellent presentation on Resistance to Treatments Targeting the RAS/RAF/MEK Pathways by Sandra Misale, PhD,
Johns Hopkins at #GI26
Genetic, nongenetic mechanisms, reshaping TME. Different patterns of resistance seen between inhibitors of specific KRAS alleles vs pan-RAS inhibitors.
Johns Hopkins at #GI26
Genetic, nongenetic mechanisms, reshaping TME. Different patterns of resistance seen between inhibitors of specific KRAS alleles vs pan-RAS inhibitors.
Great presentation on Novel Strategies for Targeting BRAF Mutation by
Elena Elez, MD, PhD, Vall d'Hebron Institute of Oncology #GI26
History, SOC, BREAKWATER, insights into combos with IO for BRAF/CMS4 and BRAF degraders.
Elena Elez, MD, PhD, Vall d'Hebron Institute of Oncology #GI26
History, SOC, BREAKWATER, insights into combos with IO for BRAF/CMS4 and BRAF degraders.
January 9, 2026 at 10:33 PM
Great presentation on Novel Strategies for Targeting BRAF Mutation by
Elena Elez, MD, PhD, Vall d'Hebron Institute of Oncology #GI26
History, SOC, BREAKWATER, insights into combos with IO for BRAF/CMS4 and BRAF degraders.
Elena Elez, MD, PhD, Vall d'Hebron Institute of Oncology #GI26
History, SOC, BREAKWATER, insights into combos with IO for BRAF/CMS4 and BRAF degraders.
Great to run into @ASCO CEO @CliffordHudis at #GI26 and to discuss progress in building a world-class cancer center #LegorretaCancerCenter at @BrownUniversity
January 9, 2026 at 8:32 PM
Great to run into @ASCO CEO @CliffordHudis at #GI26 and to discuss progress in building a world-class cancer center #LegorretaCancerCenter at @BrownUniversity
Great to meet Dr. Lawrence Wu from @Columbia @columbiacancer this morning at #GI26
The Osler tie caught my attention even though I didn’t wear mine this morning but opted for a @BrownUniversity tie.
The Osler tie caught my attention even though I didn’t wear mine this morning but opted for a @BrownUniversity tie.
January 9, 2026 at 8:28 PM
Great to meet Dr. Lawrence Wu from @Columbia @columbiacancer this morning at #GI26
The Osler tie caught my attention even though I didn’t wear mine this morning but opted for a @BrownUniversity tie.
The Osler tie caught my attention even though I didn’t wear mine this morning but opted for a @BrownUniversity tie.
Great to meet with colleagues at @JazzPharma to discuss our research on ONC201, analogues, and lurbinectedin at #GI26, including collaboration opportunities with @WIN_Consortium
January 9, 2026 at 8:23 PM
Great to meet with colleagues at @JazzPharma to discuss our research on ONC201, analogues, and lurbinectedin at #GI26, including collaboration opportunities with @WIN_Consortium
Good conversation at #GI26 with colleagues from @Bayer regarding opportunities in precision oncology and @WIN_Consortium @carisls @ccuris15
January 9, 2026 at 8:18 PM
Good conversation at #GI26 with colleagues from @Bayer regarding opportunities in precision oncology and @WIN_Consortium @carisls @ccuris15
Enjoyed speaking with Bruno @Larvol about advances in GI cancer including Claudin18.2, FGFR2, KRAS targeting, and bispecifics that have been discussed so far at #GI26
We also had a nice discussion about precision oncology and @WIN_Consortium @Dr_R_Kurzrock
We also had a nice discussion about precision oncology and @WIN_Consortium @Dr_R_Kurzrock
January 9, 2026 at 8:11 PM
Enjoyed speaking with Bruno @Larvol about advances in GI cancer including Claudin18.2, FGFR2, KRAS targeting, and bispecifics that have been discussed so far at #GI26
We also had a nice discussion about precision oncology and @WIN_Consortium @Dr_R_Kurzrock
We also had a nice discussion about precision oncology and @WIN_Consortium @Dr_R_Kurzrock
Learning about the Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/ metastatic pancreatic duct adenocarcinoma (PDAC).
Zev A. Wainberg, MD
David Geffen School of Medicine
Zev A. Wainberg, MD
David Geffen School of Medicine
January 9, 2026 at 8:03 PM
Learning about the Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/ metastatic pancreatic duct adenocarcinoma (PDAC).
Zev A. Wainberg, MD
David Geffen School of Medicine
Zev A. Wainberg, MD
David Geffen School of Medicine
Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at #GI26
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute
January 9, 2026 at 7:52 PM
Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at #GI26
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute